Atrial fibrillation (AF) is a prevalent abnormal heart rhythm that can lead to severe complications such as stroke, major bleeding, heart failure, and death. The chances of developing AF may be increased in patients with cancer and could reflect a worse prognosis. Because evidence-based treatment guidelines for patients with AF and cancer are currently not…
Results from a phase 3 open label trial (ClinicalTrials.gov Identifier: NCT01413178) published in The Lancet Haematology suggest that busulfan plus melphalan may result in longer progression-free survival (PFS) compared with melphalan alone in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation (HSCT). Patients with newly diagnosed multiple myeloma were accepted into the study…
Though adoptive T-cell transfer has demonstrated clinical applicability, many barriers prevent it from becoming a standard of care following transplant.
No difference was observed in relapse risk or survival between patients receiving phenytoin and patients receiving alternative antiepileptic medications.
Mechanical circulatory support (MCS) devices can lead to hemostatic events, making it crucial to include a hematologist on a patient’s MCS management team.
Current transfusion recommendations do not adequately inform transfusion in patients with hematologic malignancies, who are increasingly treated as outpatients.
Researchers assessed a possible association between plateletpheresis and lymphopenia when 2 platelet donors were found to have low CD4+ T-lymphocyte counts.
In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.
Consultations for palliative care for hospitalized highly symptomatic patients with cancer is low regardless of curability or whether patient has hematologic or solid cancer, a study presented at 2018 ASCO has shown.
Since brodifacoum – a long-acting vitamin K-dependent antagonist, used as a rodenticide – was detected in drug and biologic samples from patients using synthetic cannabinoids, there have been 202 reported cases of coagulopathy in 9 states (mostly Illinois; N=164)
A newly developed web site, described in a presentation at the 2018 ONS Annual Congress, aims to help nurses and patients explore clinical trial options for patients with hematologic cancers.
Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.
A cross-sectional study asked patients with hematologic cancers to name the components of care they felt were most crucial to their perception of optimal care.
A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.
Researchers examined the effect of riociguat compared with placebo on the REVEAL risk score and long-term outcomes for pulmonary arterial hypertension.
Although patients with ECD and LCH frequently have BRAFV600 mutations and respond to BRAFV600 inhibitor therapy, there was previously a lack of data describing long-term efficacy and safety.
Indications for vemurafenib are expanded to include BRAF V600 mutation-positive Erdheim-Chester disease, an extremely rare non-Langerhans cell histiocytosis. FDA approval is based on results from the phase 2 VE-BASKET study.
Researchers compared the safety and efficacy of ruxolitinib vs momelotinib, a selective JAK1/2 inhibitor, among JAK inhibitor-naïve patients with myelofibrosis.
A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.
A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.
Momelotinib, an oral JAK inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis.
A lack of needed transfusion services was cited as why many hematologic oncologists are less likely to refer their patients with blood cancers to home hospice care.
Availability of important services and adequacy of care are among the factors explaining low numbers of patients with hematologic cancers being referred for hospice care.
